Network Meta-analysis of the Benefit of Aspirin with Rivaroxaban vs. Clopidogrel for Patients with Stable Symptomatic Lower Extremity Arterial Disease

Eur J Vasc Endovasc Surg. 2021 Oct;62(4):654-655. doi: 10.1016/j.ejvs.2021.05.038. Epub 2021 Aug 25.

Authors

Graeme K Ambler¹, Joakim Nordanstig², Christian-Alexander Behrendt³, Christopher P Twine⁴

Affiliations

¹ Bristol Centre for Surgical Research, Bristol Medical School, University of Bristol, UK.
² Department of Vascular Surgery and Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska University Hospital and Academy, Gothenburg University, Sweden.
³ Research Group GermanVasc, University Medical Centre Hamburg-Eppendorf, Germany.
⁴ Bristol Centre for Surgical Research, Bristol Medical School, University of Bristol, UK. Electronic address: christopher.twine@bristol.ac.uk.

PMID: 34452837
DOI: 10.1016/j.ejvs.2021.05.038

No abstract available

Keywords: Drug therapy; Lower extremity arterial disease; Platelet aggregation inhibitors; Randomised controlled trial; Secondary prevention.

Publication types

Letter
Meta-Analysis

MeSH terms

Aged
Aspirin / adverse effects
Aspirin / therapeutic use*
Clopidogrel / adverse effects
Clopidogrel / therapeutic use*
Factor Xa Inhibitors / adverse effects
Factor Xa Inhibitors / therapeutic use*
Female
Fibrinolytic Agents / adverse effects
Fibrinolytic Agents / therapeutic use*
Hemorrhage / chemically induced
Humans
Lower Extremity / blood supply*
Male
Middle Aged
Network Meta-Analysis
Peripheral Arterial Disease / diagnosis
Peripheral Arterial Disease / drug therapy*
Peripheral Arterial Disease / physiopathology
Platelet Aggregation Inhibitors / adverse effects
Platelet Aggregation Inhibitors / therapeutic use*
Randomized Controlled Trials as Topic
Rivaroxaban / adverse effects
Rivaroxaban / therapeutic use*
Treatment Outcome

Substances

Factor Xa Inhibitors
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Rivaroxaban
Clopidogrel
Aspirin